Stockreport

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics Incorporated  (PRLD) 
PDF WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced tha [Read more]